A green and highly sensitive microwell spectrofluorimetric method with high throughput for the determination of pemigatinib based on dual fluorescence enhancement by photoinduced electron transfer blocking and micellization: Application to the analysis of tablets, content uniformity testing, and human plasma

Pemigatinib (PGT) is a recently FDA‐approved small molecule kinase inhibitor used for the treatment of relapsed or refractory myeloid/lymphoid neoplasms in adults. This study introduces the development of a first microwell spectrofluorimetric method (MW‐SFM) for quantifying PGT in FDA‐approved tablets and plasma samples. The method utilized the enhancement of PGT's weak native fluorescence by blocking photoinduced electron transfer (PET) and micellization with sodium lauryl sulfate (SLS). The MW‐SFM was performed in 96‐microwell plates, and fluorescence signals were measured using a fluorescence microplate reader with excitation at 290 nm and emission at 350 nm. The method exhibited a linear range of 2–250 ng mL−1, and a limit of quantitation was 6.5 ng mL−1. The accuracy and precision of the method were confirmed with recovery rates ranging from 96.5% to 102.8% and relative standard deviations of 1.52% to 3.51%. The MW‐SFM successfully analyzed Pemazyre® tablets, assessed content uniformity, and analyzed PGT‐spiked human plasma samples. The greenness of the MW‐SFM was verified using three different metric tools. In conclusion, the proposed MW‐SFM is a valuable tool in supporting quality assessment of dosage forms, conducting pharmacokinetic studies, and monitoring therapeutic outcomes. The study is the first attempt for the development and validation of a green and highly sensitive microwell spectrofluorimetric method with high throughput for the determination of pemigatinib based on dual fluorescence enhancement by photoinduced electron transfer blocking and micellization. The method is a valuable tool for the analysis of tablets, content uniformity testing, and human plasma samples.